ERBB2 and breast carcinoma: Interestingly, Wilson et al. reported that patients carrying TP53 mutations (mtp53) show a significantly higher probability of developing breast cancer with HER2 gene amplification (83%) when compared to the cohort of early onset breast cancer cases (16%) [12].